ChromaDex Corporation (CDXC)

NASDAQ: CDXC · IEX Real-Time Price · USD
1.610
-0.060 (-3.59%)
At close: Mar 1, 2024, 4:00 PM
1.620
+0.010 (0.62%)
After-hours: Mar 1, 2024, 7:18 PM EST
-3.59%
Market Cap 120.95M
Revenue (ttm) 83.37M
Net Income (ttm) -6.47M
Shares Out 75.12M
EPS (ttm) -0.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 37,452
Open 1.690
Previous Close 1.670
Day's Range 1.610 - 1.690
52-Week Range 1.250 - 1.990
Beta 1.86
Analysts Strong Buy
Price Target 5.00 (+210.56%)
Earnings Date Mar 6, 2024

About CDXC

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufac... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Robert N. Fried
Employees 113
Stock Exchange NASDAQ
Ticker Symbol CDXC
Full Company Profile

Financial Performance

In 2022, ChromaDex's revenue was $72.05 million, an increase of 6.82% compared to the previous year's $67.45 million. Losses were -$16.54 million, -39.03% less than in 2021.

Financial Statements

Analyst Forecast

According to one analyst, the rating for CDXC stock is "Strong Buy" and the 12-month stock price forecast is $5.0.

Price Target
$5.0
(210.56% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call ...

11 days ago - Business Wire

ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Monday, February 12, 2024

LOS ANGELES--(BUSINESS WIRE)-- #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it will be p...

27 days ago - Business Wire

ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #IR--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, today announced that its Chief E...

5 weeks ago - Business Wire

ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, is proud to announce its ...

2 months ago - Business Wire

Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+

Qualia NAD+, Featuring ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen, Well Positioned To Become Category Leader In NAD+ Supplementation. SAN DIEGO , Dec. 12, 2023 /PRNewswire/ -- ...

2 months ago - PRNewsWire

A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, shares results from a new breakth...

3 months ago - Business Wire

Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), one of the global authorities on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, shares results f...

3 months ago - Business Wire

ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow on Tuesday, November 14, 2023

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corporation (NASDAQ: CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) and healthy aging research, announced today that...

4 months ago - Business Wire

ChromaDex Corporation Reports Third Quarter 2023 Financial Results

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ: CDXC) today announced financial results for the third quarter of 2023. Third Quarter 2023 and Recent Highlights Total net sa...

4 months ago - Business Wire

ChromaDex Debuts Clinical Strength Tru Niagen® Pro 1,000mg Featuring Niagen® (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, launches its clinical stren...

4 months ago - Business Wire

ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Bioscience--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call ...

4 months ago - Business Wire

ChromaDex and Zesty Paws® Crack the Code on Cellular Health for Dogs With ‘Healthy Aging' Line

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Chewy--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, and Zesty Paws®, the #1 Selli...

4 months ago - Business Wire

A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Antiinflammatory--ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, shares results from ...

5 months ago - Business Wire

Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, shares findings from a preclinica...

6 months ago - Business Wire

ChromaDex Corporation Reports Second Quarter 2023 Financial Results

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the second quarter of 2023. Second Quarter 2023 and Recent Highlights Total net s...

7 months ago - Business Wire

ChromaDex Launches Tru Niagen® with iHerb, the World's Number One Online Destination for Health and Wellness

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #TruNiagen--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announces the appointment of the world's number one online des...

7 months ago - Business Wire

ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow Series

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), a global authority on Nicotinamide Adenine Dinucleotide (NAD+) research and healthy aging, announced today that they w...

7 months ago - Business Wire

ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, Au...

7 months ago - Business Wire

Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ARVO--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+), announced promising findings from two independent clinica...

8 months ago - Business Wire

ChromaDex, a Global Authority on Nicotinamide Adenine Dinucleotide (NAD+), Celebrates the 10th Anniversary of its ChromaDex External Research Program (CERP™), the Industry Leading Research Program Advancing the Science of NAD+ and Healthy Aging

LOS ANGELES--(BUSINESS WIRE)-- #CERP--On June 13th, ChromaDex Corp. (NASDAQ:CDXC), a global authority on nicotinamide adenine dinucleotide (NAD+) research and healthy aging, celebrated the 10th annive...

9 months ago - Business Wire

ChromaDex to Participate in the LD Micro Invitational XIII

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Lythampartners--ChromaDex Corp. (NASDAQ:CDXC) today announced that it will be participating at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevar...

9 months ago - Business Wire

ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #ChromaDex--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, today announced that its Chief Executive Officer, Rob Fried, a...

10 months ago - Business Wire

ChromaDex Corporation Reports First Quarter 2023 Financial Results

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2023. First Quarter 2023 and Recent Highlights Total net sale...

10 months ago - Business Wire

ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #Q1Earnings--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”) a global bioscience company dedicated to healthy aging, announced that it will hold a conference call ...

10 months ago - Business Wire

ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #earnings--ChromaDex Corp. (NASDAQ:CDXC) today announced fourth quarter and fiscal year 2022 financial results. Fourth Quarter 2022 and Recent Highlights Total n...

1 year ago - Business Wire